Natera (NTRA) on Monday announced a new policy for commercial coverage of its cell-free DNA fetal RhD noninvasive prenatal test in the US.
Under the new policy, coverage of fetal RhD testing will be available when a pregnancy may be facing risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy, effective January, the company said.
Natera said fetal RhD noninvasive prenatal test is offered through its women's health suite of products and can be carried out as early as nine weeks gestation.
Price: 177.74, Change: +0.82, Percent Change: +0.46
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。